Cargando...
Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3977458/ https://ncbi.nlm.nih.gov/pubmed/24715765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S37098 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|